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  Novel immunological tools for efficient diagnosis and treatment of emerging 
infections are urgently required. Advances in the diagnostic and vaccine development 
fields are continuously progressing, with Reverse Vaccinology and Structural 
Vaccinology methods for antigen identification and structure-based antigen (re)design 
playing increasingly relevant roles. Structural vaccinology, in particular, is predicted 
to be the front-runner in the future development of diagnostics and vaccines targeting 
challenging diseases such as AIDS and cancer.  
 We review state-of-the-art methodologies for structure-based epitope identification 
and antigen design, with specific applicative examples. We highlight the implications 
of such methods for the engineering of biomolecules with improved immunological 
properties, potential diagnostic and/or therapeutic uses, and discuss the perspectives 
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 Together with improved nutrition and hygiene, efficient disease diagnosis and 
vaccination are medicine landmarks that have promoted major improvements in 
human health and longevity [1, 2]. In diagnostics, significant progress has been 
observed in the development of disease-specific probes, in the types of materials used 
for their presentation, and in the sensitivity of the associated detection methods. It is 
now possible to design new (bio)molecules that recognize specific biomarkers (see 
Glossary), such as antibodies (Abs) elicited in response to infection, and improve our 
understanding of the molecular mechanisms underlying the immune response [3]. The 
impacts of such advances are particularly visible in fields where diagnosis typically 
required invasive techniques or complex scanning machineries. In parallel, vaccines 
offer great potential to tackle infectious diseases caused by emerging pathogens, 
multi-drug resistant bacteria, parasites and viruses, and lately in the treatment of 
cancer and HPV, or HIV and even Ebola [4-7]. Vaccines help prevent and/or cure 
diseases by activating the immune system against (future) attacks. A fundamental step 
in the delivery of protective vaccines has been, and is, the development of new 
approaches to the discovery and engineering of protein antigens (Ags) capable of 
eliciting apt immune responses.  
 Epitopes, the specific molecular regions of an antigen that are recognized in the 
immune response, may represent ideal immunoreagents that can be conjugated to 
other known immunogens (proteins and otherwise), or presented in combination with 
other epitopes on chemical or biological scaffolds, increasing their applicative 
potential as diagnostics and vaccine components [8]. A holistic approach, integrating 
both diagnostic probe and vaccine candidate design, is summarized in Figure 1.  
 Here, we review novel avenues and perspectives for Ag/epitope discovery and 
engineering in immunodiagnostics and vaccinology, based on the combination of 
protein 3D structures, in silico analyses and design strategies. We discuss specific 
applicative examples and highlight their implications for engineering synthetic 
molecules with improved immunological properties for diagnostic and/or therapeutic 
applications. Notably, although much of the research discussed originated from the 
need to combat specific infectious diseases, the scope of the approaches we present is 
vast, and in principle transferable to any disease-related Ag of known 3D structure.  
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Bioinformatics antigen selection: the Reverse Vaccinology revolution  
In contrast to classical methods based on attenuated or killed pathogen 
particles to prompt the host immune response, modern vaccinology can rely on Ag 
discovery via bioinformatics; Reverse Vaccinology (RV; Box 1) explores pathogen 
genomes to identify Ags for downstream in vivo validation as vaccine candidates [9, 
10]. Potential Ag genes are picked out from the bacterial genome via bioinformatic 
mining for specific sequence motifs, such as those encoding for outer membrane 
proteins, and then produced in an appropriate expression system (e.g. Escherichia 
coli) for testing. The extension of RV to explore multiple related pathogenic genomes, 
so-called Pan-genomic RV (PRV), can support the discovery of candidate Ags that 
cross-protect against diverse bacterial strains. The impact of RV has been exemplified 
by the identification of four protective Ags that formulate BexseroR, the first vaccine 
targeting Neisseria meningitidis serotype B infections [11].  
Since bioinformatics analyses may yield large numbers of candidates, to 
reduce the number of proteins to be expressed-purified for in vivo phases, further 
methodological developments have been proposed, taking into account recurring 
structural/functional features (protective signatures) of known protective Ags, in order 
to better select bactericidal molecules [12]. When applied to Staphylococcus aureus 
and Group B Streptococcus, such 'protectome' analyses identified two previously 
unknown Ags, and 'rediscovered' known ones [12].  
 
The role of structural studies in Ag engineering 
Ag discovery can be efficiently supported by structure-based design concepts. 
In this context, Structural Vaccinology (SV) (see Glossary and Box 1), whereby 3D 
information is used to reveal the determinants of Ag stability and conformational 
dynamics underlying molecular recognition by the immune system, has recently 
emerged as a new driving force in immunology. Advances in X-ray crystallography, 
Nuclear Magnetic Resonance (NMR) and single particle Cryo-Electron 
Microscopy (Cryo-EM), are in fact facilitating the study of challenging Ags, 
particularly when applied to Ag and Ag-Ab complex structures and interaction studies 
[9, 13, 14].  
Coupled to in vitro epitope mapping data and computer-aided Ag engineering, 
3D structural knowledge can pinpoint the location and physico-chemical properties of 
the epitopes that are ultimately responsible for triggering B-cell and/or T-cell 
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mediated immune responses [15] (Figure 1). Structural knowledge on epitopes can 
also drive the design of peptide-based mimics (or libraries), epitope-containing 
protein domains, or completely new Ags that on one hand are reactive versus disease 
biomarkers, and on the other can elicit bacteria-neutralizing responses [9, 13]. 
Successful achievements of SV include applications to the Respiratory Syncytial 
Virus fusion protein Ag and the Factor H binding protein (FHbp) Ag from MenB, 
respectively [11, 16].  
To progress along such promising avenues, we must address fundamental 
questions: 1) can we formulate general principles that allow immune-reactive and 
non-reactive epitope substructures to be distinguished?; 2) is it possible to design 
peptide-based epitope mimics (to be presented in multiplex or multivalent formats) as 
diagnostic probes that detect specific biomarkers?; 3) is it possible to translate epitope 
knowledge into the design of 'super-Ags' presenting multiple T-/B-cell epitopes that 
induce better protection compared to their single epitope counterparts? In fact, 
epitope-based vaccines can offer several advantages: they may be more readily 
produced on an industrial scale, are easily presented through diverse delivery vessels 
and adjuvants, and may be engineered to improve their antigenicity. In diagnostic 
applications, the possibility of displaying multiple reactive epitopes from one 
pathogen can facilitate the transition towards high-throughput approaches.  
 
 
Epitope discovery and design 
The first prerequisite to meet the above challenges is our ability to predict and 
locate epitope regions as privileged Ag-substructures capable of selectively engaging 
molecules of the immune system. 
 
a) Epitope predictors based on general molecular properties 
 Computational methods for epitope prediction are playing increasingly 
important roles, thanks to continuous technological advances in computing. Moreover, 
a number of databases such as the Immune Epitope DataBase (www.iedb.org) [17], 
AntiJen [18], and the international ImMunoGeneTics (IMGT) [19] have been devised 
to collect experimental epitope sequence data, and to provide tools for the discovery 
of new epitopes, whilst providing information on those already mapped.  
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 Although the precise criteria that determine immunogenic properties remain 
elusive, a number of molecular features shared by effective epitopes have been 
observed. Examples include localized physico-chemical properties, such as 
hydrophobicity, solvent-exposure, flexibility or lack of sequence conservation. Such 
observations led to the development of several computational algorithms. Notable 
examples of servers that predict B-cell epitopes through the combination of different 
molecular properties into a single predictor include ElliPro [20] 
(http://tools.immuneepitope.org/ellipro/) and SEPPA[21] 
(http://lifecenter.sgst.cn/seppa/). 
 
b) Sequence-based epitope predictors 
 Due to the linear nature of T-cell epitopes, in silico sequence-based methods 
that predict both MHC class I and, to a lesser-extent, MHC class II molecule 
presentation, can be highly accurate. Recent examples include MULTIPRED [22], 
TEPITOPE (Human Leukocyte Antigen (HLA) class I) [23], and ProPred [24] (HLA 
class II predictor). It must be underlined that these approaches identify epitopes based 
on their predicted HLA binding affinities, and no information on their potential 
immunogenicity is revealed.  
 Predictions of B-cell epitopes, targeted by Abs in the initial stages of the 
immune response, are more challenging, since 3D structure information is typically 
required. Sequence-based methods were previously limited to the prediction of linear 
epitopes, however tools for the prediction of conformational epitopes, which 
represent a large subset of all B-cell epitopes, including many capable of inducing 
bactericidal responses [25], have recently emerged thanks to machine learning 
approaches [26, 27] 
 
c) Structure-based epitope predictors  
 As the interplay between sequence and conformational properties underpins 
Ab binding, prediction methods based on explicit consideration of Ag structural 
dynamics have great potential for epitope discovery and design. One such method, 
called the Matrix of Low Coupling Energies (MLCE), implemented in a webserver 
(BEPPE, Binding Epitope Prediction from Protein Energetics, 
http://bioinf.uab.cat/BEPPE/)[28] analyzes the dynamic and energetic properties of 
Ag structures, and identifies contiguous surface-located residues that build low 
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intensity interaction networks with designated core protein regions [29]. Such 
substructures are not required for global stabilization of the Ag, may tolerate 
mutations and may be highly dynamic, all hallmarks of typical B-cell epitopes. 
MLCE, whose predictions reach promising accuracy (AUC 0.71), has been tested 
against Ags from diverse bacterial pathogens. Successful application to Chlamydia 
and Burkholderia pseudomallei Ags led to the identification of epitopes with both 
therapeutic and diagnostic implications [30-33]. MLCE/BEPPE can also be combined 
with energy domain decomposition methods to fragment proteins into sub-domains 
[34] prior to epitope predictions, revealing 'hidden epitopes' that may evade 
identification but be potentially interesting in generating immune responses [35] 
(Figure 2). Importantly, these energy-based strategies proved successful for 
identifying conformational epitopes. This task is now becoming increasingly feasible 
thanks to the soaring numbers of Ag and Ag-Ab 3D complex structures in the Protein 
Data Bank (http://www.rcsb.org).  
The accuracy of the fore-mentioned methods may be further enhanced by 
combining them with approaches that focus on diverse physico-chemical properties. 
As for protein-protein interactions in general, Ab-Ag binding involves displacement 
of water molecules bound at the interaction interfaces: the Electrostatic Desolvation 
Profiles (EDP) method scans the protein surface, looking for solvent-accessible clefts 
and calculates the theoretical desolvation penalty for each site, upon binding of a 
protein partner, selecting those where water displacement is favored [36]. 
 
 
Synthetic epitope mimics: structure-activity relationships. 
Information on the immunoreactive potential of epitopes coupled to the 
synthetic accessibility of peptides opens the way to chemical interventions aimed to 
modulate their structures and to assess how specific conformational ensembles affect 
Ab-recognition. One approach is to constrain peptides into the desired conformation 
by means of covalent modifications, such as stapling and macrocyclization [37-39]. 
Ideally, a stapling strategy may be a versatile tool to produce synthetic epitopes that 
closely mimic the conformational space of their native counterparts, such as loops and 
turns. For instance, the correct spacing between extremities of a loop can be achieved 
through a suitable macrocyclization process, or through the inclusion of PEG moieties 
mimicking the spatial distance between them [35]. 
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This rationale was applied to a computationally-predicted epitope (Pal3) from 
the pathogenic bacterium Burkholderia pseudomallei (Figure 3) that was found to be 
strongly immunoreactive [40]. In the cognate Ag, the epitope adopts an α-helical 
conformation; when synthesized as a free peptide, in contrast to the full-length protein, 
the epitope mimic could clearly discriminate between melioidosis patient serogroups, 
and elicited bactericidal Abs. In the free peptide form, however, the epitope was 
unable to retain its α-helical conformation and, accordingly, exhibited poor stability in 
plasma. A 1,4-disubstituted-1,2,3-triazole staple was introduced to block the D-helical 
fold of Pal3, which improved both its half-life in human plasma and patient IgG 
recognition. In contrast, the Abs generated against the stapled peptide proved 
significantly less bactericidal than those elicited against the unconstrained epitope 
[40]. This observation was reconciled considering that, when housed in the 
recombinant Ag, the epitope region may undergo local folding-unfolding reactions 
that present different conformations to the polyclonal pools of generated Abs. 
Blocking a single conformation in the stapled synthetic epitope may thus give rise to a 
limited pool of Abs that recognize fewer epitope conformations. Such restrictions 
were not observed for the unstapled version of Pal3. In contrast, conformational 
preorganization of the synthetic epitope was found to improve its diagnostic 
performance, most likely by increasing affinity for specific Abs, translating into better 
readable signals. While the Pal3 case was one of the first reports of a stapling strategy 
applied to a peptide with diagnostic applications, these results suggest that the balance 
between conformational freedom and immunogenicity deserve more extended 
investigations [30, 40]. 
An additional notable example of epitope stapling involves the SAH-MPER 
linear epitope from the HIV gp41 protein. The constrained epitope was remarkably 
resistant to proteolysis, and was able to recapitulate its native antigenic properties by 
binding neutralizing Abs with high affinity [39]. The stapling technique used in this 
case involved the direct linkage of two carbon atoms within the epitope.  
 
Multi-presentation of designed epitopes  
Peptides mimicking Ab-recognition motifs of different Ags are ideal tools for 
multiplex approaches, whereby multiple epitopes can be presented simultaneously, 
both for detection of (multiple) biomarkers and for the induction of improved immune 
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responses (Figures 1,4; Box 2). The potential of peptide multiplex display methods 
has recently been demonstrated [41-43]. Multiplex approaches can significantly 
contribute to the serological detection of infections, and can discriminate between Ab 
classes (IgM, IgG, IgA), thus providing crucial information on infection type and 
disease progression (i.e. acute or chronic phases). The combination of responses 
originated from probe diversity/redundancy can facilitate the analysis and 
interpretation of results and ultimately can shed light on infection status, identify 
patient subgroups, discriminate between different pathogens (and their variants) and 
assist in medical decision-making. A further advantage is that multiplex diagnostics, 
based on large peptide libraries spotted on a single chip, are practically simple and 
therefore can be used on-site in hospitals, offering fast and accurate diagnosis that 
accelerates therapeutic decisions. This is extremely advantageous for low-income 
countries where infection outbreaks may be difficult to contain, but also in developed 
countries where new and re-emerging infections are on the increase, as underlined by 
recent pandemics (e.g. Ebola and Zika viruses). 
In this framework, Kodadek et al. have recently demonstrated the use of 
peptoid libraries to mimic the molecular shapes in antigen space, to map the antigen-
binding pockets of disease-specific Abs [3]. In one notable example, by screening 
around a million compounds, the authors found a subgroup that preferentially bound 
human IgGs from HIV positive patients. Reactive peptoids were re-synthesized and 
singularly evaluated: the most responsive one allowed serodiagnosis of HIV [44]. 
Another case reported the detection of Burkholderia cepacia complex 
infections from sera of Cystic Fibrosis (CF) patients using a peptide-based microarray 
platform [32]. In this case, peptide-mimics of predicted Ag-Ab binding interfaces 
were identified and chemically optimized for click-chemistry controlled orientation 
on the microarray surface. The resulting platform, displaying multiple Burkholderia-
related epitopes was able to correctly diagnose infected individuals even in the face of 
superinfections caused by other prevalent CF pathogens [32]. The time and cost for 
the analysis were contained, and the results demonstrated that a peptide microarray 
approach may elucidate Burkholderia sp. infection even at the subtype level. 
 
Multi-presentation: from nanoparticles to structure-based epitope grafting  
One of the most exciting perspectives for computational epitope engineering is 
the development of new vaccines, and of novel epitope delivery vessels as agents 
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promoting the immune response. A possible multiplex approach based on 
nanocarriers is illustrated in Figure I, Box 3 
 These carriers can be mainly of two kinds: inorganic (e.g. gold) nanoparticles 
(AuNPs) functionalized with antigenic epitopes, and vesicular nanoparticles, 
composed of vesicles or liposomes, capable of carrying the Ags on their surface or 
inside the bilayer. Products based liposomal carriers are already commercial, such as 
Inflexal® V against influenza and Epaxal® against Hepatitis A [45]. One of the 
advantages of this technology is that lipid composition can be adjusted to meet 
desired properties, including size to accommodate the cargo, charge (charged 
liposomes are able to enhance the innate immune response stimulation [46], fluidity, 
or the inclusion of immunostimulatory lipids such as CAF01 [47] or D-
galactosylceramide [48].  
Concerning epitope presentation and delivery, liposomes may accommodate 
different epitopes encapsulated in the aqueous core or displayed at the surface. 
Epitope attachment can be mediated by covalent- or hydrophobic-anchors adsorbed 
through the lipid layer. Alternatively, the epitope may be designed and synthesized to 
include a transmembrane helix to promote liposome [49] attachment. Such versatility 
allows optimal display of synthetic epitopes: for instance, they may be presented 
directly to immature B-cells adsorbed or linked at the surface of the nanocarriers. On 
the other hand, T-cell epitopes may be encapsulated within the bilayer, and optimized 
in size and composition to be internalized by Ag-presenting cells, where the 
nanovesicles can release their cargo. It is known that different vesicles may promote 
uptake by different cellular types, so to favor MHC-I or MHC-II presentation [50-52]. 
One such approach was tested with good results by Irvine and coworkers, who 
simultaneously displayed the membrane proximal external region from the B-cell 
HIV epitope gp41 on the surface of the liposome, with a T-cell epitope (HIV-30) 
encapsulated within the internal region of the liposome [53]. Other advantages of 
using vesicle-based carriers include good tolerability and safety; importantly, they are 
completely biodegradable (Figure I, Box 3).  
Evolving these technologies for vaccine purposes is a hot research topic [52]. 
Even if a protocol that gives rise to neutralizing protection has yet to be demonstrated, 
some encouraging results have been achieved [54]. Such studies hint at the possibility 
of using nanoparticles not only as viable carriers, but also to promote a boost in 
 10 
immunogenicity compared to the use of the individual Ags, a common plus of 
nanocarriers. This aspect introduces further potential for rational engineering of the 
immunological response. Liposomes and nanoparticles can be in fact prepared to 
display a large diversity of epitopes, recapitulating the immunogenic determinants of 
many Ags into a single component. Also, the carriers can be optimized for specific 
tasks: diffusion, stability, stimulation of one specific branch of the adaptive immune 
response, act as cytokine carriers, act as adjuvants, or they can be designed to carry 
over many tasks at the same time. Compared to the typical subunit vaccine, the 
increase in complexity is high but the technological gain and the possibilities that they 
open are highly exciting.   
 
Chimeras 
Among the strategies that employ the rational design of Ags and epitopes, we 
consider the case of “chimeras” as a particularly interesting one [16] (Figure 4). One 
Ag can be characterized for sequence similarity across multiple pathogenic variants; 
then, assisted by 3D structural data, it is possible to assess the differences that define 
the variant-specific neutralizing epitopes. A series of mutations that encompass the 
regions of variability as well as specificity, can lead to a single recombinant Ag able 
to trigger a neutralizing effect in multiple strains, as successfully accomplished for 
factor H binding protein (fHbp) from Neisseria meningitidis group B (MenB) [55]. In 
this case, a broadly reactive Ag was requested in order to induce protection against all 
major MenB strains and, along with the other Ags in the formulation, to provide an 
effective vaccine. The objective was met by screening many different variants and 
mutations; however, this process may benefit from additional knowledge on the 
structural features of Ag-Ab recognition (e.g. Ags co-crystallized with FABs of 
selective Abs). In this regard, computational studies integrating sequence 
conservation across variants (bioinformatics) and Ag-Ab binding modeling and 
optimization (computational chemistry) or crystal structures, may help focus on a 
smaller set of “hotspot” residues within the epitope, thus reducing residue 
permutations to those that are more prevalent across the strains of interest, eventually 




Computational design of proteins to host foreign functional motifs can give 
rise to Ags with new functionalities or diverse immunological properties. This 
strategy, termed ‘epitope grafting’, can be used to selectively stabilize suitable 
conformations of epitopes for immune presentation or to address antigenic variability 
of diverse pathogenic species (Figure 5, Box 4). Simultaneous presentation of 
multiple epitopes on the same scaffold is known to induce stronger and more durable 
immune response. For some pathogens, in particular of intracellular nature, joint cell-
mediated and humoral immune responses are required for a sterilizing vaccine. It has 
been shown that immunization with chronic and acute phase Mycobacterium 
tuberculosis Ags on the same polypeptide chain, induces a better protective response 
in comparison to administering both Ags separately [56]. As an alternative to 
expressing the full-length forms of multi-Ags on the same polypeptide chain, epitope-
grafting strategies could be adopted to combine both T-cell and B-cell epitopes within 
the same protein scaffold. 
For successful epitope grafting, a main prerequisite is the availability of a 
protein scaffold that presents a 3D structure reflecting or compatible with that of the 
target Ab recognition motif to be transplanted. The field is evolving rapidly, but it has 
yet to reach its full potential. Using the Fold From Loops (FFL) method that designs 
scaffold proteins hosting new functional motifs, a neutralizing epitope from human 
respiratory syncytial virus (RSV) glycoprotein was grafted onto an unrelated protein 
scaffold, which elicited neutralizing Abs [57]. A recent report describing an 
automated tool for the implantation of immunogenic epitopes onto a given scaffold, 
named SAGE (Strategy for Alignment and Grafting of Epitopes), was published. The 
method considers both sequence and structure conservation between target epitopes 
and scaffolds, and is fully applicable to any protein from any pathogen for which the 




 Health challenges posed by globalization underline the growing request for 
delivery of protective vaccines at immediate notice; recent examples of viral 
outbreaks in Central Africa are just one of many examples. Antigens/epitopes that 
induce protective antibodies are the main components in vaccine formulations; 
nevertheless, classical methods of antigen selection cannot cope with such urgent 
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therapeutic requests. A new, more rational avenue involving the in silico screening of 
pathogen genomes, and taking advantage of our theoretical knowledge on protein 
structure, dynamics and recognition, provides a more rapid and economical 
alternative to conventional antigen discovery approaches. Further to antigen selection, 
in silico methods have also been demonstrated to accurately predict epitopes from 
sequence and 3D structure information, adding a powerful arm to vaccine design 
strategies. Despite such initial achievements, and a few successful application cases, 
the full potential of SV has yet to be exploited (see Outstanding Questions Box). In 
fact, general structural rules and the general applicability of antigen engineering 
approaches, such as chimeras or epitope grafting on existing protein architectures, are 
foreseen in the near future. Furthermore, antigen/epitope display on carriers such as 
nanoparticles, vesicles or liposomes are increasingly attractive approaches to vaccine 
design. The current technological control of the production of such decorated carrier 
species must be adequately met by systematic in vivo analyses of their immunologic 
and protective properties. 
 Health challenges must also be faced through adequate diagnostic capabilities. 
Due to extensive migration of world populations, pathogen diffusion between 
continents is increasing, calling for rapid, robust and practically facile diagnostic tests 
for use in hospitals and refugee camps/centers to diagnose, and contain, emerging 
infections. In this context, protein antigens/epitopes can be used to detect the presence 
and phase of pathogen infection by monitoring their recognition by cognate serum 
antibodies. The predictive capabilities acquired through the application of 
fundamental principles of protein structure recognition are therefore translating into 
new bio-reagents for the assembly of diagnostic tools based on microarray display 
technologies. Here, engineering of antigens/epitopes in a multiplex context is the most 
promising approach, given the possibility of multiple diagnostic queries on the same 
support, which can aptly translate in an efficient profiling of the disease and disease 
state, thus favoring patient stratification and therapeutic decision-making. 
 As in other branches of life sciences, genomic data and fundamental 
information on protein structure and dynamics are fostering the development of 
translational science. It is expected that vaccines and immunodiagnostics will soon 
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Adjuvant: a substance that potentiates an immune response, and a fundamental 
component of vaccine formulations. 
Antibody:   An antibody (or immunoglobulin) is a protein composed of two heavy- 
and two light-chains that is secreted by B-cells in response to an antigen. 
Antigen:  A protein antigen is a pathogen-derived protein that triggers the host 
immune response. Antigens can also be based on oligosaccharides or other 
macromolecules. 
Antigenic variability: the interspecies-dependent sequence variability of an epitope 
region from the same antigen, often acquired by a pathogen to evade the host immune 
response. 
B-cell: Antibody-secreting cell, and key player in humoral immunity; also termed B-
lymphocyte. 
Bioinformatics: computational tools developed and applied to analyze data provided 
by genomic or protein sequencing projects. 
Biomarker: a biological molecule that is characteristic of a given physiological or 
pathological process; it can be exploited for detection/diagnosis.  
Cell-mediated immune response: the human immune response branch mediated by 
phagocytic cells, T-cells and cytokines. 
Click-chemistry: the introduction of chemical staples to constrain the 3D 
conformation of a macromolecule. 
Epitope: the antigen portion that stimulates an immune response. It stimulates T-cells 
or B-cells, depending on the nature of the epitope. 
Epitope grafting: computer-guided transplantation of a (conformational) epitope 
onto a heterogeneous protein scaffold.  
Half-life: the time required for an entity to decrease to half its initial value.  
Human Leukocyte Antigen complex: HLA, a cell surface protein complex 
governing the human immune response and human equivalent to the major 
histocompatibility complex.   
Humoral immune response: the branch of the human immune response triggered by 
antigens or pathogens circulating in the blood, which are recognized by B-cells and 
stimulate antibody secretion from plasma cells. 
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Major Histocompatibility Complex: MHC, Protein complex present on the cell-
surface in all vertebrates that helps the immune system recognize foreign substances 
by binding to antigens and presenting them to T-cells.  
Multiplex: the presentation of multiple biomarkers on a suitable vessel. 
Neutralizing Abs: Antibodies that eradicate a pathogen from the body. 
Nuclear Magnetic Resonance: Spectroscopy-based analytical technique used to 
determine 3D structures by exploiting the magnetic properties of atomic nuclei 
arranged within a (macro)molecule. 
Peptoid: poly-N-substituted glycine residues that are protease-resistant peptide 
mimics. 
Reverse Vaccinology: a bioinformatics-based approach to Ag identification, starting 
from pathogen genome sequence data.  
Structural Vaccinology: the use of 3D structure information to guide specific 
engineering of antigens endowed with improved biochemical and/or immunological 
properties. 
T-cell: Front-runner in cell-mediated immunity. There are several types of T-cell (or 
T-lymphocyte) that trigger and facilitate diverse types of immune response.  
X-ray crystallography: A biophysical technique that reveals the 3D arrangement of 
atoms in a crystallized (macro)molecule, based on the application of X-rays whose 
wavelength approximately matches the typical dimensions of atomic level features, 
which are therefore resolved in the electron density maps. 
 
 
Text Boxes  
x BOX 1: Reverse Vaccinology and Structural Vaccinology in Vaccine 
Development 
 Since the genomic advent in 2000, which led to increasing pathogen genome 
sequence information, bioinformatics-based methods for antigen selection (termed 
Reverse Vaccinology, RV) have taken over laborious and time consuming 
conventional approaches that require pathogen cultivation [10, 59]. RV methods 
predict surface-exposed or secreted proteins that are the first point of contact for 
immune system molecules as potential antigens, based on the presence of signal 
peptides and/or other sequence motifs that imply cell surface location, e.g. 
transmembrane regions, sortase recognition motifs, and sequence conservation 
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with known antigens. When multiple pathogen species genomes are available, RV 
can be extended to identify proteins pertaining to the pan-genome, shared by all 
species, whose common antigens could potentially protect against more than one 
species. In silico selected candidate antigens are subsequently validated for their 
effective immunological properties in vitro and in in vivo animal models.  
 Since protein antigen immunogenicity is directly determined by overall three-
dimensional fold, conformations and related dynamics, unsurprisingly, structure-
based antigen design followed closely on the heels of RV (originating Structural 
Vaccinology, SV). Based on 3D structure information, structural modifications 
such as the introduction of disulfide bonds can be strategically introduced to block 
typically transient conformations of neutralizing epitopes or antigens, as 
exemplified by the Respiratory Syncytial Virus (RSV) glycoprotein F antigen 
[15]. Alternatively, SV can be used to design epitope-containing domains that 
may be easily produced in recombinant form for industrial-scale production, as an 
alternative to the full-length antigen. Moreover, mutations can be introduced in 
epitope regions to account for interspecies sequence variability to generate cross-
protective antigens.  In short, SV can be used to specifically tailor protein antigens 
that can be rapidly produced for immediate testing of their biochemical and/or 
immunological properties.  
x BOX 2: Multiplex diagnostics based on microarray approaches.  
The distinctive trait of microarray technologies is the simultaneous detection 
of a panel of different molecules in a single experiment. In general, in analytical 
microarrays, target bait molecules are immobilized on a surface, creating a 
collection of probes that are able to "fish" complementary protein targets out of a 
biological sample [60, 61]. Unbound molecules are then removed by washing, and 
captured ligands are detected using labeled reporters, typically secondary 
antibodies. Arrays consist of a rigid support (e.g. a glass microscope slide) 
modified by suitable surface chemistry to immobilize bait probes in microspots of 
100-250 μm diameter, spatially ordered in matrix format.  
For antibody and biomarker detection, proteins and peptides are immobilized as 
capturing agents, whereas a labeled anti-immunoglobulin is used for detection. 
This is the scheme typically used for allergy tests (to detect allergen specific 
immunoglobulins E), infectious disease diagnosis (pathogen specific 
immunoglobulins G or M detection) and autoimmunity diagnostics. In this 
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context, peptide microarrays offer potentially unlimited flexibility as they can be 
designed to identify any antibody-binding domain that can subsequently be 
implemented in vaccine development. Design of epitope collections from RV- or 
SV-selected antigens may generate a large amount of molecular and 
immunological information by mining the Ab content present in plasma of 
individual patients, profiling immuno-responses to infection, vaccination etc. 
Importantly, peptides (relatively economical to produce and more managable 
compared to DNA or proteins) in a miniaturized and multiplexed format test can 
simultaneously screen for dozens to thousands of biomarkers in a single assay. 
Different chemistries for surface display are now available. Epitope-based 
microarrays exploit thus the structural and recognition properties of epitopes from 
target protein antigens to detect specific antibody-biomarkers. The main 
advantage in this kind of approach resides in the ability to comparatively analyze 
results from libraries of baits while exploiting the combination of responses 
originated from probe redundancy.  
The maturity of the technique has been proven by the many published clinical 
applications and by the several commercial providers offering support and 
services.  
x BOX 3: Nanocarriers for epitopes 
Chemistry at the nanoscale is providing useful approaches to address 
biologically-relevant problems (Figure I). Particles and molecular machines of nm 
dimensions are being increasingly and more extensively used as drug-delivery 
tools for targeted therapeutics, for instance in cancer applications. In the context 
of vaccine delivery systems, nanotechnology can provide new solutions for the 
development of safe and effective products. In principle, by linking several 
different antigens (even of different chemical origin, e.g. proteins and 
carbohydrates) on the same carrier, it is possible to create highly reactive systems 
that may provide strong and durable protection: several studies have proven this 
potential, by encapsulating antigens to improve their stability or to promote 
presentation by displaying antigens on the nanoparticle surface. In this context, 
gold nanoparticles (AuNPs) have generated huge interest thanks to their 
biocompatibility, low toxicity, imaging properties and the ability to release 
antigens at specific sites through targeting [62]. In the case of peptide-based 
epitope mimics, the facile approaches to link peptides to the surfaces based on 
 18 
sulfur-gold chemical reactivity allows for the versatile inclusion of structurally 
diverse sequences.  
In the nanoparticle field, Outer Membrane Vesicles (OMVs) represent an 
innovative technology that allows several Ags (of e.g. bacterial or cancer origin) 
to be expressed and displayed on the vesicle surface. OMVs are heterogenous 
spheroid particles (10–300 nm in diameter) generated through the budding out of 
the bacterial outer membrane in Gram-Negative bacteria. OMVs purified from 
several pathogens proved to induce protective immune responses against the 
pathogens they derive from. Importantly, anti-Neisseria OMV-based vaccines are 
already available for human use [63-65]. Such remarkable protection can be 
linked to the fact that: they carry surface-associated protective antigens; they are 
readily phagocytosed by antigen-presenting cells, favoring presentation of 
antigen-derived peptides; and OMVs carry pathogen-associated-molecular 
patterns which target pathogen recognition receptors stimulating both innate 
adaptive immune responses. In the context of rational vaccine design, a key 
feature of OMVs is the possibility to manipulate their protein content and surface 
display by genetic engineering, directing protein expression to the outer 
membrane of the OMV-producing strain. This would clearly favor to development 
of highly effective multi-valent vaccines. Finally, such nanoparticles are gaining 
increasing attention for their inbuilt adjuvant capabilities. All these properties 
make nanoscale-type materials ideal reagents to be combined with structure-
based, rational antigen and epitope design. 
x BOX 4: Epitope grafting approaches for multiple epitope presentation 
Most infections are characterized by diverse phases, for example acute and 
chronic phases, which require activation of both humoral and cell-mediated 
immune responses; thus, both B- and T-cell epitopes are vital components of 
protective vaccine formulations. Simultaneous, rather than consecutive 
presentation of epitopes is known to trigger stronger and more durable immune 
responses, therefore multiple epitopes should ideally be presented on the same 
polypeptide chain or via the same chemical scaffold. With regards to protein-
based scaffolds, atomic level structure data and computational biology design 
methods can be used to remove an epitope from its host antigen and to transplant 
it onto a conformationally-apt region of an entirely different recipient protein 
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(Figure 5). This can endow the grafted epitope with new and improved 
immunological properties. For example, in its parental antigen, a neutralizing 
epitope may be masked by other less important, yet conformationally dominant 
epitopes; transplanting it to a new scaffold may improve its accessibility to the 
molecules governing the immune response. When the protein scaffold itself is an 
antigen, epitope grafting can be used to present multiple epitopes, e.g. T- and B-
cell epitopes to trigger both the innate and humoral immune responses. In this 
case, attention must be made to ensure that the grafted epitope does not mask the 






Figure 1 – An overview of the different structure-based computational methods that 
are described in this review, starting from selection of conformational or linear 
epitopes originating, e.g.,from a viral capsid or from a protein antigen. 
Figure 2 – A scheme of the different stages through which the Matrix of Low 
Coupling Energies method  (MLCE) proceeds: from an antigen 3D structure and MD 
simulation, through the analysis of internal energetics and contacts, to prediction of 
uncoupled protein regions that can represent epitopes. 
Figure 3 – A graphics representation of chemical methods that allow stabilizing an 
epitope conformation through cross-linking or ‘stapling’. 
Figure 4 – Broadly reactive antigens, able to trigger a neutralizing effect vs. multiple 
pathogenic strains, can be designed through the creation of chimeric proteins hosting 
mutations of variant-specific neutralizing epitopes in a single recombinant protein. 
The figure highlights the hot spots in the final product identified by Scarselli and 
coworkers in a broadly protective MenB antigen. 
Figure 5 – Epitopes recognized within a given antigen can be transplanted onto a 
different antigen, to boost its immunogenic properties, provided that the 
conformational context in which the new epitope is to be grafted is compatible with 
its original structure. 
Figure I, Box 3 – A schematic representation of the potential offered by decoration of 
nanoparticle or vesicles with peptide epitopes identified through the computational 
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Outstanding Questions Box  
 
x Technological advances in computing are steadily growing, while hardware is getting 
cheaper and cheaper: can this turn into in silico analyses that help predict antigens and 
epitopes more directly/accurately? 
x Given the increasing number of 3D structures provided by X-ray crystallography, there will 
be an increasing possibility of generating homology models for newly discovered antigens. 
Will these modeled structures allow accurate epitope prediction? 
x Will computational methods be able carry out large-scale predictions on all available 
antigen structures, and to generate peptide libraries for immediate screening for 
diagnostic/therapeutic potential?  
x Will we be able to formulate basic sequence/structural principles and integrate them into 
existing in silico epitope prediction methods to take predictions one step further and 
discriminate protective from non-protective epitopes, ultimately predicting vaccinological 
protection in humans? 
x Will the above mentioned approaches be combined in methods that integrate big data from 
disparate sources (structural, clinical, epidemiological) as the basis for machine learning, 
artificial intelligence approaches aimed at predicting immunologic potential from 
sequence/structure information? 
x Will epitope-grafted antigens presenting multiple T-/B-cell epitopes induce better protection 
with regards to their single counterparts? 
x Can optimal carriers for epitope presentation be designed rationally and immediately applied 
to disparate needs? 
x Will it be possible to overcome current limitations in diagnostic accuracy using multiple 
highly-selective epitopes as probes? 
x Will epitope-based diagnostic solutions be able to use a single drop of blood  or saliva? 
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